Recent schizophrenia research supports a model, wherein aberrant brain changes in late-adolescence contribute to the onset and early progression of disease. 1 To further examine this model, longitudinal studies of genetic high-risk subjects, including those in prodromal stage, have recently been conducted. 2 Parallel studies evaluating patients with recent-onset schizophrenia are growing in number. 3 Nonetheless, almost all these studies are limited to clinical and neuropsychological characterization, and to brain imaging. Therefore, the molecular mechanisms underlying these dynamic changes remain elusive.
In order to address this fundamental question with better molecular understanding, we have examined the cerebrospinal fluid (CSF) from patients with recent-onset schizophrenia (within the first five years of disease) and have compared these samples to those from age-matched healthy controls and patients with chronic schizophrenia (five or more years of schizophrenia) (Supplementary Table 1 ). Building on the hypothesis that oxidative stress and associated neuroinflammatory response may have a role in this dynamic process, 4 we measured the levels of 14 selected molecules (Supplementary Table 2) .
Here, we report the novel finding of a dramatically reduced level of soluble superoxide dismutase-1 (SOD1) in CSF from patients with recent-onset schizophrenia in contrast to samples from age-matched healthy controls (Table 1 , Supplementary  Figure 1) . Furthermore, the level of CSF-soluble SOD1 from recent-onset patients is lower than that from patients with chronic schizophrenia. To our knowledge, this is the first report of decreased CSF SOD1 in recent-onset schizophrenia. We also highlight that although the sample size of patients with 1 year or less disease is small, the absolute concentrations of soluble SOD1 are most robustly decreased in this cohort. We speculate that the decrease in soluble SOD1 between patients with 1 year or less disease and age-matched healthy controls is limited in significance by the small sample size.
Although our reported observations require replication in a larger sample, this study implies two innovative conceptual contributions. First, the reduction of soluble SOD1 may directly underlie oxidative stress at the onset of schizophrenia through decreased availability of this important antioxidant enzyme. We further note that this decrease in CSF-soluble SOD1 concentration could be a secondary effect of another pro-oxidative process. Nevertheless, this ultimate decrease in soluble SOD1 is likely to facilitate overall oxidative stress. Thus, we provide further evidence of the 'oxidative stress hypothesis' in schizophrenia. Second, we note the possibility that a decrease in CSF-soluble SOD1 may reflect an increase in 'insoluble' SOD1. This is analogous to decreased Ab1-42 in CSF from patients with Alzheimer's disease reflecting insoluble Ab1-42 and senile plaques. 5 Likewise, SOD1 is amyloidogenic and can be associated with brain disorders, such as amyotrophic lateral sclerosis. 6 We wish to recall that aggregate formation in Huntington's disease and other brain disorders has been discovered only after specific probing of target molecules, such as Huntingtin detection using a specific antibody. 7 Therefore, it is crucial to now explore insoluble SOD1 in autopsied brains or biopsied cells (for example, induced neurons from fibroblasts, and olfactory neurons) from patients with recent-onset schizophrenia, and such future studies may utilize antibodies against insoluble forms of SOD1. 8 A role of misfolded protein in schizophrenia has also been suggested by studies stemming from genetic susceptibility factors. Korth and associates 9 reported the recruitment of Dysbindin protein to cell-invasive DISC1 aggresomes, suggesting the important convergence of two promising genetic risk factors and the significance of protein insolubility in cases of schizophrenia.
The levels of CSF-soluble SOD1 are not significantly different between chronic cases and matched healthy controls (data not shown). The possible contrast in SOD1 between recent-onset schizophrenia and chronic cases may be addressed in follow-up studies with larger sample size. It is possible that transient downregulation around the onset of schizophrenia might have an important pathophysiological role. Of note, some studies suggest that neuroleptic medication might increase plasma or serum SOD levels, 10 although levels between peripheral blood and CSF are not necessarily correlated. In this report, with one exception, all patients were on medication at the time of CSF acquisition.
In summary, we report diminished CSF-soluble SOD1 in cases of recent-onset schizophrenia and discuss this observation as supporting the previously proposed role of 'oxidative stress' in the pathophysiology and onset of this disease. Increased oxidative stress can lead to synaptic deterioration and interneuron deficits relevant to the pathophysiology of schizophrenia. Furthermore, this observation may also be an entry point for other working hypotheses, such as those of SOD1 protein misfolding and aberrant control of proteolysis, which prompt further investigation. A recently completed genome-wide association study (GWAS) implicated single-nucleotide polymorphisms in the MIR137 gene as being highly associated with schizophrenia. 1 MIR137 encodes for the microRNA miR-137, which has been implicated in the regulation of adult neurogenesis 2 and neuron maturation. 3 Strikingly, four predicted targets of miR-137 also achieved genome-wide significance. These findings suggest that the dysregulation or dysfunction of miR-137 may be a novel pathological pathway underlying the etiology of schizophrenia.
In this work, we use a luciferase-based reporter assay to demonstrate the site-specific regulation of CSMD1, C10orf26, CACNA1C and TCF4 by miR-137. Schizophrenia is a spectrum disorder that has a lifetime prevalence of B1%. Disease onset usually occurs during adolescence, and suicide is the leading cause of premature death. Although monozygotic twin studies have clearly shown a genetic basis for this disease, the underlying genetics of schizophrenia have been difficult to delineate. A linkage study of a Scottish family with a high incidence of psychiatric disorders identified a rare, but highly penetrant, mutation in disrupted in schizophrenia-1 (DISC1); 4 however, single-gene mutations have not been found in the vast majority of schizophrenia patients. It is believed that the onset of schizophrenia is due to the accumulation of several gene mutations, each of which has modest phenotypic effects, which are compounded with environmental factors. This complexity has made the identification of contributing genes difficult. Improvements in genotyping technology have allowed for GWAS in large patient populations. However, the results of schizophrenia GWASs have yet to be validated biologically.
In a recent study by the Schizophrenia Psychiatric GWAS consortium, MIR137, along with four of its putative targets (CSMD1, C10orf26, CACNA1C and TCF4) were reported to have genomewide significant associations with schizophrenia. 1 In addition, genes associated with schizophrenia were enriched for predicted miR-137 targets. These findings imply that miR-137 dysregulation or dysfunction may be a pathway that contributes to schizophrenia disease progression. Until this report, schizophrenia GWAS findings have not been linked to the neurobiology of the disease. To investigate the biological relevance of schizophrenia GWAS findings, we used reporter constructs to directly confirm miR-137-mediated knockdown of predicted miR-137 target sequences in the 3 0 -untranslated regions of four putative schizophrenia risk genes.
The CSMD1, C10orf26, CACNA1C and TCF4 predicted miR-137 target gene 3 0 -untranslated regions have either 7mer or 8mer canonical sites and, in some cases, are elaborated with a 3 0 -supplementary site (Figure 1a) , as defined previously. 5 These five sites (TCF4 has two predicted miR-137 sites) and their flanking sequences were cloned into the 3 0 -untranslated region of Renilla luciferase in the psiCHECK-2 vector (Figure 1b ) and co-transfected with either miR-CNTL or miR-137 overexpression constructs at a 1:2 ratio into HEK-293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). HEK-293T cells have a low endogenous level of miR-137 expression (data not shown). The psiCHECK-2 vector also includes Firefly luciferase driven by a separate promoter that allows for normalization of signal to transfection efficiencies. When the ratio of Renilla to Firefly luciferase activity was compared between cells transfected with miR-CNTL and those with miR-137, all predicted targeted showed decreased Renilla luciferase activities by 25--50% compared with controls ( Figure 1c) . When the miR-137 7mer site 5 0 -GCAAUAA-3 0 was deleted from each target construct and co-transfected with miR-137, the Renilla/Firefly luciferase ratio did not differ significantly from controls (P40.05 two-way analysis of variance). These results show that miR-137 interacts with the 3 0 -untranslated region sequences from the four predicted targets in a site-specific manner.
MiR-137 has been shown to have a role in epigenetic regulation of adult neural stem cell proliferation 2 and neuronal maturation. 3 This is analogous to the phenotypes following knockdown of the schizophrenia-related gene DISC1. 6 In addition, two predicted miR-137 targets have been previously associated with psychiatric illness. CACNA1C encodes for the a subunit of the voltagedependent L-type calcium channel Ca V 1.2, and has been shown to be associated with bipolar disease.
7 TCF4 encodes a transcription factor involved in the development of a subset of neural progenitors 8 and TCF4-overexpressing transgenic mice show schizophrenia-associated behavior. 9 These studies, and the recent
